Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials

Jul 31 2020

• By Joseph Haas

Team_Puzzle — The merger complete, AbbVie unveiled its combined earnings with Allergan

Related Content

AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval

Apr 24 2019

AbbVie’s Five Biggest Priorities, Apart From Allergan

Jul 26 2019

Skyrizi Launch Skyrockets, Boosting AbbVie Hopes For Humira Successors

Nov 01 2019

Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib

Oct 25 2019

Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches

Jan 31 2020

AbbVie Presents Optimistic Take For 2020, Expects Quick Recovery For Botox Aesthetic

May 01 2020

AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis

Jul 22 2020

AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval

Aug 16 2019

Related Companies

AbbVie Inc.

Allergan plc

Amgen, Inc.

Gilead Sciences, Inc.

Galapagos NV

Additional Topics

Sales & Earnings Business Strategies M & A Companies Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window